

In the Claims:

Claims 1-9 (Previously cancelled).

Claim 9. (Previously Presented) A method for the treatment and/or prophylaxis of a disease in a mammal in need thereof, which disease is characterized by androgenic dependency, comprising administering to the mammal an effective amount of a neurokinin-3 receptor antagonist.

Claim 10. (Previously Presented) The method of claim 9 wherein the androgen is testosterone.

Claim 11. (Previously Presented) The method according to claim 9, wherein the disease is selected from BPH, metastatic prostatic carcinoma, testicular cancer, androgen dependent acne, male pattern baldness, precocious puberty in boys, hyperandrogenism, hirsutism, virilization, POCS, HAIR-AN syndrome, ovarian hyperthecosis, follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility, androgen-producing tumors.

Claim 12. (Previously Presented) A method for suppressing testosterone production in a mammal comprising administering to the mammal an effective amount of a neurokinin-3 receptor antagonist.

Claims 13. (Previously Presented) A method of suppressing the production of luteinizing hormone in a mammal comprising administering to the mammal an effective amount of a neurokinin-3 receptor antagonist.

Claims 14-16 (Cancelled).

Claim 15. (New) The method according to claim 9, wherein the disease is benign prostatic hyperplasia.

Claim 16. (New) The method according to claim 9, wherein the neurokinin-3 receptor antagonist is selected from

((S)-(-)-N-(α -Ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide);
(S)-(-)-N-(α -Ethylbenzyl)-3-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-2-phenylquinoline-4-carboxamide;
(+)-(R)-3-[3-(4-Phenyl-4-N-methylacetamidopiperidin-1-yl)propyl]-3-(3,4-dichlorophenyl)-1-benzoylpiperidine;

(S)-(-)-N-(α -Ethylbenzyl)-3-(3-carboxy)propoxy-2-phenylquinoline-4-carboxamide;
and
(S)-(-)-N-(α -Ethylbenzyl)-3-carboxymethoxy-2-phenylquinoline-4-carboxamide.

Claim 17. (New) The method according to claim 16, wherein the neurokinin-3 receptor antagonist is ((S)-(-)-N-(α -Ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide).